Recombinant Adeno-Associated Virus Encoding Methyl-CPG Binding Protein 2 for Treating PITT Hopkins Syndrome VIA Intrathecal Delivery
AssigneeResearch Institute At Nationwide Children's Hospital
InventorsKathrin Christine Meyer, Cassandra Nicole Dennys-Rivers
Life of this patent
Estimating the term…
Abstract
Methods and materials for treating Pitt Hopkins Syndrome comprising intrathecal delivery of recombinant Adeno-associated virus 9 (rAAV9) encoding Methyl-CpG binding protein 2 (MECP2) are provided.
Claims36
A method of treating Pitt Hopkins Syndrome comprising administering a recombinant adeno-associated virus (rAAV9) encoding Methyl-CpG binding protein 2 (MECP2) to a subject in need thereof.
A method of increasing Methyl-CpG binding protein 2 (MECP2) levels in a subject suffering from Pitt Hopkins Syndrome comprising administering a recombinant adeno-associated virus (rAAV9) or a rAAV viral particle encoding MECP2 to the subject.
A method of delivering a polynucleotide sequence encoding the Methyl-CpG binding protein 2 (MECP2) to a subject suffering from PTHS comprising administering a recombinant adeno-associated virus (rAAV9) or a rAAV viral particle encoding MECP2 to the subject.
A composition for treating Pitt Hopkins Syndrome wherein the composition comprises a recombinant adeno-associated virus (rAAV9) encoding Methyl-CpG binding protein 2 (MECP2).
A composition for increasing Methyl-CpG binding protein 2 (MECP2) levels in a subject suffering from Pitt Hopkins Syndrome wherein the composition comprises a recombinant adeno-associated virus (rAAV9) or a rAAV viral particle encoding MECP2 to the subject.
A composition for delivering a polynucleotide sequence encoding the Methyl-CpG binding protein 2 (MECP2) to a subject suffering from PTHS wherein the composition comprises a recombinant adeno-associated virus (rAAV9) or a rAAV viral particle encoding MECP2 to the subject.
Use of a recombinant adeno-associated virus (rAAV9) encoding Methyl-CpG binding protein 2 (MECP2) for the preparation of a medicament for treating Pitt Hopkins Syndrome (PTHS) in a patient in need thereof.
Use of a recombinant adeno-associated virus (rAAV9) encoding Methyl-CpG binding protein 2 (MECP2) for the preparation of a medicament for increasing Methyl-CpG binding protein 2 (MECP2) levels in a subject suffering from Pitt Hopkins Syndrome
Use of a recombinant adeno-associated virus (rAAV9) encoding Methyl-CpG binding protein 2 (MECP2) for the preparation of a medicament for delivering a polynucleotide sequence encoding the Methyl-CpG binding protein 2 (MECP2) to a subject suffering from PTHS.
Dependencies are inferred from the claim text.